
News|Articles|January 29, 2024
Alternative buffer management strategies to achieve downstream process improvements
Author(s)Avantor
Buffers are used in great quantities when producing monoclonal antibodies (mAbs), and many biopharmaceutical companies — even large ones — do not have the processing capacity or infrastructure in-house to handle these large volumes. Whether it’s providing quality, pre-weighed, GMP-compliant raw materials or the entire buffer preparation step, there are options available to optimize your process.
Trending on Pharmaceutical Technology
1
Using Automation to Enhance Pharmaceutical Manufacturing
2
Regulatory Actions Impacting Biologics
3
The FDA Moves to Modernize Drug Manufacturing Registration
4
Munnik Revisits His 2026 Predictions: A Midyear Check-In on Regulatory Reform, Data, and AI in Pharma
5